FCGR3A and neoplasm: In association with the progress in the development of tumor-targeting mAbs and their engineered variants with higher ADCC activity, various methods of measuring ADCC have been developed.[20], [21], [36]–[38] However, most of these assay methods were designed to estimate ADCC mediated by NK cells via FcγRIIIa, and the contribution of FcγRIIa was hardly detected.